|
1）Granger CB, Armaganijan LV. Should newer oral anticoagulants be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism? Circulation. 2012; 125: 159-64
|
|
|
|
2）Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-51
|
|
|
|
|
|
3）Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-91
|
|
|
|
|
|
4）Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J. 2012; 76: 2104-11
|
|
|
|
|
5）Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-92
|
|
|
|
|
|
6）Ruft CT, Glugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE-AF TIMI 48). Am Heart J. 2010; 160: 635-41
|
|
|
|
|
|
7）Hori M, Connolly SJ, Zhu J, et al. Dabigatran versus warfarin: Effect on ischemic and hemorrhagic strokes and bleeding in asian and non-asians with atrial fibrillation. Stroke. 2013; 44: 1891-6
|
|
|
|
|
|
8）Banerjee A, Lane DA, Torp-Pedersen C, et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ʻreal worldʼ atrial fibrillation population: A modeling analysis based on a nationwide cohort study. Thromb Haemost. 2012; 107: 584-9
|
|
|
|
|
|
9）Diener H-S, Connoly S, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol. 2010; 9: 1157-63
|
|
|
|
|
|
10）Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attacl: a subgroup analysis of ROCKET AF. Lancet Neurol. 2012; 11: 315-22
|
|
|
|
|
|
11）Tanahashi N, Hori M, Matsumoto M, et al. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation fot the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis. 2013. In press
|
|
|
|
|
|
12）Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient iscaemic attack: a subgroup analysis of the ARISTOTLE trial. Lancet Neurol. 2012; 11: 5030511
|
|
|
|
|
|
13）Fox KAA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011; 32: 2387-94
|
|
|
|
|
|
14）Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123: 2363-72
|
|
|
|
|
|
15）Oldgren J, Allings M, Darilus H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011; 155: 660-7
|
|
|
|
|
|
16）Hori M, Connolly SJ, Erekowitz MD, et al. Efficacy and safety of dabigatran vs. warfarin in patients with atrial fibrillation -sub-analysis in Japanese population in RE-LY trial. Circ J. 2011; 75: 800-5
|
|
|
|
|
|
17）Freeman JV, Zhu RP, Owens DK, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011; 154: 1-11
|
|
|
|
|
|
18）Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012; 110: 845-51
|
|
|
|
|
|
19）Lee S, Mullin R, Blazawski J, et al. Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation. PloS One. 2012; 7: e47473
|
|
|
|
|
|
20）Schulman S, Crowther MA. How I treat anticoagulation in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012; 119: 3016-23
|
|
|
|
|
|
21）Ogawa S, Koretsune Y, Yasaka M, et al. Antithrombotic therapy in atrial fibrillation. Circ J. 2011; 75: 1539-47
|
|
|
|
|
|
22）Camm AJ, Lip GY, De Caterina R, et al. 2012 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012; 33: 2719-47
|
|
|
|
|
|
23）Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation. A science advisory for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012; 43: 3442-53
|
|
|
|
|
|
24）Toyoda K, Yasaka M, Uchiyama S, et al. Blood pressure levels and bleeding events during antithrombotic therapy. The bleeding with antithrombotic therapy (BAT) study. Stroke. 2010; 41: 1440-4
|
|
|
|
|